晚期慢性肝病临床进展的阶段特异性驱动因素
研究前瞻性纳入464例晚期慢性肝病患者,在肝静脉压力梯度测量时入组,用多状态模型分析阶段转换风险及生物标志物的阶段特异性预后价值。结果显示代偿期以门脉高压、内皮功能障碍、纤维生成和肝功能受损为进展指标,失代偿期转向全身炎症和肝功能,进一步失代偿期加循环功能障碍。
要点
- 代偿期优先靶向门脉高压,失代偿期调节全身炎症和循环功能障碍至关重要
- 肝静脉压力梯度和白蛋白在代偿期提供独立预后信息
- C反应蛋白在失代偿期、和肽素在进一步失代偿期提供独立预后信息
核心结论
- 代偿期优先靶向门脉高压,失代偿期调节全身炎症和循环功能障碍对预防进展关键,基于个体生物标志物的精准医学可能优化未来临床试验患者结局
研究设计与样本
- 前瞻性队列研究,纳入464例晚期慢性肝病患者,2017至2021年在肝静脉压力梯度测量时入组(VICIS;NCT03267615),中位随访35个月,用多状态模型分析阶段转换风险
主要发现
- 代偿期患者(n=179)24个月时13%发生首次失代偿,2.8%发生进一步失代偿/慢加急性肝衰竭,1.9%肝相关死亡,失代偿后0.9%发生再代偿
- 失代偿期肝硬化患者(n=168)19%发生进一步失代偿/慢加急性肝衰竭,6.1%肝相关死亡,8.0%实现再代偿
- 基线进一步失代偿患者(n=117)12个月时33%肝相关死亡,3.0%再代偿
- 门脉高压、内皮功能障碍、纤维生成和肝功能受损指示代偿期进展,失代偿期转向全身炎症和肝功能,进一步失代偿期加循环功能障碍
关键数值与推荐
- 肝静脉压力梯度和白蛋白在代偿期提供独立预后信息
- C反应蛋白在失代偿期提供独立预后信息
- 和肽素在进一步失代偿期提供独立预后信息
临床怎么用
- 代偿期应优先针对门脉高压进行管理
- 失代偿期应重视调节全身炎症和循环功能障碍以预防疾病进展
- 可根据个体生物标志物谱进行精准医学管理,未来临床试验可据此优化患者结局
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Different pathophysiological mechanisms contribute to the progression of advanced chronic liver disease. This study investigated the clinical trajectory of advanced chronic liver disease in a contemporary cohort and evaluated biomarkers reflecting key pathophysiological mechanisms for their stage-specific prognostic value. METHODS: Patients with advanced chronic liver disease (n = 464) were prospectively recruited at hepatic venous pressure gradient measurement between 2017 and 2021 (VICIS; NCT03267615). Clinical states at baseline and follow-up were defined as compensated advanced chronic liver disease, first decompensation, further decompensation/acute-on-chronic liver failure (combined), liver-related death, and recompensation. Multistate modeling was used to investigate the risk of stage transitions during follow-up (median 35 months). The association of biomarkers for portal hypertension (hepatic venous pressure gradient), endothelial dysfunction (von Willebrand factor), liver fibrogenesis (Enhanced Liver Fibrosis score), liver function (Model for End-stage Liver Disease/albumin/bile acids), systemic inflammation (C-reactive protein/interleukin-6/procalcitonin), and circulatory dysfunction (N-terminal prohormone of brain natriuretic peptide/copeptin) with stage transitions was evaluated. RESULTS: In patients with compensated advanced chronic liver disease (n = 179), 13% developed first decompensation at 24 months, 2.8% developed further decompensation/acute-on-chronic liver failure, 1.9% experienced liver-related death; and 0.9% developed recompensation after decompensation. In decompensated cirrhosis (n = 168), 19% developed further decompensation/acute-on-chronic liver failure and 6.1% experienced liver-related death, whereas 8.0% achieved recompensation. Among patients with further decompensation at baseline (n = 117), 33% experienced liver-related death and 3.0% recompensation at 12 months. Portal hypertension, endothelial dysfunction, fibrogenesis, and impaired liver function were indicative of progression in compensated advanced chronic liver disease, shifting towards systemic inflammation and liver function in decompensated cirrhosis, with the additional contribution of circulatory dysfunction in further decompensation. Hepatic venous pressure gradient and albumin provided independent prognostic information in compensated advanced chronic liver disease, C-reactive protein in decompensated cirrhosis, and copeptin in further decompensation. CONCLUSIONS: Targeting portal hypertension should be prioritized in compensated advanced chronic liver disease, whereas modulating systemic inflammation and circulatory dysfunction is crucial for preventing disease progression in decompensated cirrhosis. Precision medicine based on individual biomarker profiles could optimize patient outcomes in future clinical trials. CLINICALTRIALS: gov, Number: NCT03267615.
引用
- Simbrunner B, Semmler G, Bofill Roig M, et al. Stage-Specific Drivers of Clinical Progression in Advanced Chronic Liver Disease. Clin Gastroenterol Hepatol. 2026. PMID: 42309430. doi:10.1016/j.cgh.2026.06.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。